Menstrual cups and cash transfer to reduce sexual and reproductive harm and school dropout in adolescent schoolgirls in western Kenya: a cluster randomised controlled trial.
Adolescent girls
Cash transfers
HIV
HSV-2
Kenya
Menstrual cups
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
21
04
2023
revised:
15
09
2023
accepted:
22
09
2023
medline:
20
10
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
epublish
Résumé
High rates of sexual and reproductive health (SRH) harms and interrupted schooling are global challenges for adolescent girls, requiring effective interventions. We assessed the impact of menstrual cups (MCs) or cash transfers conditioned on school attendance (CCTs), or both, on SRH and schooling outcomes in western Kenya. In this cluster-randomised Cups or Cash for Girls (CCG) trial, adolescent girls in Forms two and three at 96 secondary schools in Siaya County (western Kenya) were randomised to receive either CCT, MC, combined CCT and MC, or control (1:1:1:1) for an average of 30 months. The CCT intervention comprised 1500KES (US$15 in 2016) via a cash card each school trimester. All four treatment groups received puberty and hygiene training. Assenting girls with parent or guardian consent who were post-menarche, not pregnant, area residents, not boarding, and had no disabilities precluding participation were eligible. Socio-behavioural risk factors and incidence of HIV and herpes simplex virus type 2 (HSV-2) were measured annually. School retainment and adverse events were monitored throughout. The primary outcome comprised a composite of incident HIV, HSV-2 and/or all-cause school dropout by school exit examination. The primary analysis was by intention-to-treat (ITT) using generalised linear mixed models, controlling for Between February 28, 2017 and June 30, 2021, 4137 girls (median age 17.1 [interquartile range (IQR): 16.3-18.0]) were enrolled and followed annually until completion of secondary school (median 2.5 years [IQR: 2.4-2.7]); 4106 (99.3%) contributed to the ITT analysis. No differences in the primary composite outcome between intervention and control groups were seen (MC: 18.2%, CCT: 22.1%, combined: 22.1%, control: 19.6%; adjusted risk ratio [aRR]: 0.97, 95% confidence interval 0.76-1.24; 1.14, 0.90-1.45; and 1.13, 0.90-1.43, respectively). Incident HSV-2 occurred in 8.6%, 13.3%, 14.8%, and 12% of the MC, CCT, combined and control groups, respectively (MC: RR: 0.67, 0.47-0.95, p = 0.027; aRR: 0.71, 0.50-1.01, p = 0.057; CCT: aRR: 1.02, 0.73-1.41, p = 0.92; combined aRR: 1.16, 0.85-2.58, p = 0.36). Incident HIV was low (MC: 1.2%, CCT: 1.5%, combined: 1.0%, and control: 1.4%; aRR: 0.88, 0.38-2.05, p = 0.77, aRR: 1.16, 0.51-2.62, p = 0.72, aRR: 0.80, 0.33-1.94, p = 0.62, respectively). No intervention decreased school dropout (MC: 11.2%, CCT: 12.4%, combined: 10.9%, control: 10.5%; aRR: 1.16, 0.86-1.57; 1.23, 0.91-1.65; and 1.06, 0.78-1.44, respectively). No related serious adverse events were seen. MCs, CCTs, or both, did not protect schoolgirls against a composite of deleterious harms. MCs appear protective against HSV-2. Studies of longer follow-up duration with objective measures of health impact are needed in this population. Department of Health and Social Care, the Foreign, Commonwealth & Development Office, the Medical Research Council and Wellcome.
Sections du résumé
Background
UNASSIGNED
High rates of sexual and reproductive health (SRH) harms and interrupted schooling are global challenges for adolescent girls, requiring effective interventions. We assessed the impact of menstrual cups (MCs) or cash transfers conditioned on school attendance (CCTs), or both, on SRH and schooling outcomes in western Kenya.
Methods
UNASSIGNED
In this cluster-randomised Cups or Cash for Girls (CCG) trial, adolescent girls in Forms two and three at 96 secondary schools in Siaya County (western Kenya) were randomised to receive either CCT, MC, combined CCT and MC, or control (1:1:1:1) for an average of 30 months. The CCT intervention comprised 1500KES (US$15 in 2016) via a cash card each school trimester. All four treatment groups received puberty and hygiene training. Assenting girls with parent or guardian consent who were post-menarche, not pregnant, area residents, not boarding, and had no disabilities precluding participation were eligible. Socio-behavioural risk factors and incidence of HIV and herpes simplex virus type 2 (HSV-2) were measured annually. School retainment and adverse events were monitored throughout. The primary outcome comprised a composite of incident HIV, HSV-2 and/or all-cause school dropout by school exit examination. The primary analysis was by intention-to-treat (ITT) using generalised linear mixed models, controlling for
Findings
UNASSIGNED
Between February 28, 2017 and June 30, 2021, 4137 girls (median age 17.1 [interquartile range (IQR): 16.3-18.0]) were enrolled and followed annually until completion of secondary school (median 2.5 years [IQR: 2.4-2.7]); 4106 (99.3%) contributed to the ITT analysis. No differences in the primary composite outcome between intervention and control groups were seen (MC: 18.2%, CCT: 22.1%, combined: 22.1%, control: 19.6%; adjusted risk ratio [aRR]: 0.97, 95% confidence interval 0.76-1.24; 1.14, 0.90-1.45; and 1.13, 0.90-1.43, respectively). Incident HSV-2 occurred in 8.6%, 13.3%, 14.8%, and 12% of the MC, CCT, combined and control groups, respectively (MC: RR: 0.67, 0.47-0.95, p = 0.027; aRR: 0.71, 0.50-1.01, p = 0.057; CCT: aRR: 1.02, 0.73-1.41, p = 0.92; combined aRR: 1.16, 0.85-2.58, p = 0.36). Incident HIV was low (MC: 1.2%, CCT: 1.5%, combined: 1.0%, and control: 1.4%; aRR: 0.88, 0.38-2.05, p = 0.77, aRR: 1.16, 0.51-2.62, p = 0.72, aRR: 0.80, 0.33-1.94, p = 0.62, respectively). No intervention decreased school dropout (MC: 11.2%, CCT: 12.4%, combined: 10.9%, control: 10.5%; aRR: 1.16, 0.86-1.57; 1.23, 0.91-1.65; and 1.06, 0.78-1.44, respectively). No related serious adverse events were seen.
Interpretation
UNASSIGNED
MCs, CCTs, or both, did not protect schoolgirls against a composite of deleterious harms. MCs appear protective against HSV-2. Studies of longer follow-up duration with objective measures of health impact are needed in this population.
Funding
UNASSIGNED
Department of Health and Social Care, the Foreign, Commonwealth & Development Office, the Medical Research Council and Wellcome.
Identifiants
pubmed: 37860578
doi: 10.1016/j.eclinm.2023.102261
pii: S2589-5370(23)00438-8
pmc: PMC10582356
doi:
Banques de données
ClinicalTrials.gov
['NCT03051789']
Types de publication
Journal Article
Langues
eng
Pagination
102261Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
We declare no competing interests.
Références
BMJ Glob Health. 2022 Jan;7(1):
pubmed: 35027438
BMJ Open. 2016 Nov 23;6(11):e013229
pubmed: 27881530
J Infect Dis. 2015 Jul 1;212(1):8-17
pubmed: 25589333
BMC Public Health. 2019 Oct 21;19(1):1317
pubmed: 31638946
AIDS. 2008 Jul 31;22(12):1493-501
pubmed: 18614873
PLoS Med. 2021 Oct 25;18(10):e1003837
pubmed: 34695112
BMC Int Health Hum Rights. 2011 Jun 16;11:7
pubmed: 21679414
Glob Health Action. 2016 Dec 08;9:33032
pubmed: 27938648
Reprod Health. 2018 Jan 27;15(1):15
pubmed: 29374479
J Biosoc Sci. 2009 May;41(3):409-27
pubmed: 19036174
Lancet Public Health. 2019 Aug;4(8):e376-e393
pubmed: 31324419
AIDS Behav. 2010 Jun;14(3):469-82
pubmed: 19949847
Lancet. 2012 Apr 7;379(9823):1320-9
pubmed: 22341825
Lancet Glob Health. 2016 Dec;4(12):e978-e988
pubmed: 27815148
Am J Public Health. 2015 Jul;105(7):1302-11
pubmed: 25973831
J Adolesc Health. 2018 Jan;62(1):44-51
pubmed: 29107569
PLoS One. 2015 Dec 04;10(12):e0144321
pubmed: 26636771
EClinicalMedicine. 2021 May 07;35:100876
pubmed: 34027335
Am Econ Rev. 2015 Sep;105(9):2757-97
pubmed: 26523067
PLoS One. 2013 Nov 14;8(11):e79132
pubmed: 24244435
PLoS Med. 2021 Sep 28;18(9):e1003756
pubmed: 34582445
PLoS Med. 2023 Jul 25;20(7):e1004258
pubmed: 37490459
Lancet Infect Dis. 2017 Dec;17(12):1303-1316
pubmed: 28843576
J Womens Health (Larchmt). 2011 Feb;20(2):303-11
pubmed: 21194348
PLoS One. 2022 Feb 7;17(2):e0262858
pubmed: 35130299